1、首次公开发行股票募集资金情况 根据中国证券监督管理委员会（以下简称"中国证监会"）《关于核准山东 联科科技股份有限公司首次公开发行股票的批复》（证监许可[2021]1813号）， 山东联科科技股份有限公司获准向社会公开发行人民币普通股（A股）股票 45,500,000.00股，每股发行价格14.27元，募集资金总额为649,285,000.00元， 减除发行费用52,972,160.39元后，募集资金净额596,312,839.61元。上述资金 于2021年6月16日全部到位，已经会计师事务所验证并出具永证验字（2021）第 210018号《验资报告》予以确认。 2、2023 年度以简易程序向特定对象发行股票募集资金情况 根据中国证券监督管理委员会（以下简称"中国证监会"）《关于同意山东 联科科技股份有限公司向特定对象发行股票注册的批复》（证监许可[2023]1285 号），山东联科科技股份有限公司获准以简易程序向特定对象发行人民币普通股 18,561,464 股 ， 每 股 发 行 价 格 为 人 民 币 14.48 元 ， 共 计 募 集 人 民 币 268,769,998.72 元，扣除不含税发行费 ...

（原标题：谢方敏辞任董事会主席兼CEO；百洋医药与多家医疗机构展开合作） 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 徐景和在受理和举报中心调研并开展接访下访 12月9日，国家药监局官微发文显示，国家药监局党组成员、副局长徐景和在受理和举报中心调研受理 和举报工作并开展接访下访，听取两家医疗器械、化妆品企业相关诉求，进行了现场沟通和答复。徐景 和指出，要科学把握安全与发展、监管与服务的关系，坚持依法行政、科学监管，有效保障企业合法权 益，助力产业高质量发展。要深刻认识当前投诉举报工作面临的新形势、新任务，坚持法治思维，依法 依规解决投诉举报事项，推进社会共治取得新成效。 药械审批 苑东生物：布瑞哌唑片获得药品注册证书 欧莱雅将增持高德美10%股份 高德美（瑞士证券交易所：股票代码为"GALD"）宣布：欧莱雅集团拟增加对该公司的股权投资，将从 Sunshine SwissCo GmbH处额外收购 10% 的股份。Sunshine SwissCo GmbH是由殷拓集团（EQT）、阿 布扎比投资局（ADIA）及Auba Investment Pte. Lt ...

宣武医院 启动脑转移瘤精准放疗IIT研究。百洋医药供图 转自：北京日报客户端 12月8日，中国颅内转移瘤协作组（CLAIM）学术论坛暨首都医科大学宣武医院ZAP-X研究者发起的临 床研究（IIT）启动仪式召开。此次IIT研究由宣武医院与百洋医药合作开展，宣武医院神经外科主任张 鸿祺担任主要研究者，旨在进一步探索全球领先的脑肿瘤精准放疗设备——ZAP-X放射外科机器人在脑 转移瘤患者中的临床疗效与安全性、剂量学特征。 在脑转移瘤精准治疗需求迫切的背景下，本次IIT研究由中国颅内转移瘤协作组提供学术指导，宣武医 院神经外科发起并负责实施。所谓IIT研究，是指由医生、科研人员等临床研究者自主设计研究方案， 而非由药品或医疗器械企业主导发起的临床研究。研究围绕ZAP-X放射外科机器人展开，该设备由国际 神经外科领域的权威学者、射波刀发明人约翰•艾德勒教授研发，专门针对脑部精准放疗而设计。 ZAP-X采用全球首创的双回旋球形结构，可产生数千条非共面射束，能够在精准打击肿瘤靶区的同时最 大限度保护周围健康脑组织。该设备具备亚毫米级精度，并集成实时影像引导与实时剂量双重监控，在 脑部放疗最核心的精准、安全两大维度上实现突破 ...

证券之星消息，12月8日橡胶板块较上一交易日上涨1.43%，科创新源领涨。当日上证指数报收于 3924.08，上涨0.54%。深证成指报收于13329.99，上涨1.39%。橡胶板块个股涨跌见下表： 从资金流向上来看，当日橡胶板块主力资金净流入219.47万元，游资资金净流入1415.34万元，散户资金 净流出1634.81万元。橡胶板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | | 主力净占比 游资净流入 (元) | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603650 | 彤程新材 | 5005.57万 | 4.51% | 6813.98万 | 6.14% | -1.18 Z | -10.66% | | 300320 海达股份 | | 1811.01万 | 12.84% | -209.90万 | -1.49% | -1601.11万 | -11.36% | | 920225 | 利通科技 | 1095.65万 | 8.27% | 559.99万 | 4.23% | ...

Core Points - The company held its third extraordinary general meeting of shareholders in 2025, with no proposals rejected or modified during the meeting [2][3] - The meeting was conducted both in-person and via online voting, with a total of 117 shareholders representing 107,530,810 shares, accounting for 49.6616% of the total voting shares [9][10] Meeting Details - The meeting was convened by the board of directors and chaired by Chairman Wu Xiaolin [4] - The in-person meeting took place on December 4, 2025, at 15:00, with online voting available from 9:15 to 15:00 on the same day [5][6] - The record date for shareholding was November 27, 2025 [7] - The meeting location was at the company's conference room in Weifang City, Shandong Province [8] Attendance - A total of 117 shareholders attended, representing 107,530,810 shares [9] - Among them, 10 shareholders attended in person, representing 106,877,310 shares, while 107 shareholders participated via online voting, representing 653,500 shares [10][11] - Small and medium-sized shareholders accounted for 1,836,797 shares, or 0.8483% of the total voting shares [13] Resolutions and Voting Results - The first resolution approved was to conclude the fundraising investment projects and permanently supplement the remaining funds into working capital, with 99.7334% of votes in favor [15][17] - The second resolution involved changing the auditing firm from Yongtuo to Zhihong for the 2025 fiscal year, also receiving 99.7326% approval [19][20] Legal Opinion - The meeting was witnessed by lawyers from Beijing Deheheng Law Firm, who confirmed that the meeting's procedures and voting results complied with relevant laws and regulations [20]

北京德和衡律师事务所 BE IJING DHH LAW FIRM 北京德和衡律师事务所 关于山东联科科技股份有限公司 2025年第三次临时股东会的 法律意见书 德和衡证见意见（2025）第223号 中国·北京市朝阳区建国门外大街 2 号银泰中心 C 座 11、12 层 电话： (+86 10) 8540 7666 邮编：100022 www.deheheng.com 北京德和衡律师事务所 关于山东联科科技股份有限公司 2025年第三次临时股东会的 法律意见书 德和衡证见意见（2025）第223号 致：山东联科科技股份有限公司 北京德和衡律师事务所（以下简称"本所"）接受山东联科科技股份有限公司（以下简称 "公司"或"贵公司"）的委托，指派本所律师出席贵公司 2025 年第三次临时股东会。本所 律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、 《山东联科科技股份有限公司章程》（以下简称"《公司章程》"）及相关法律法规以及规范 性文件的规定，就本次股东会的有关事宜出具本法律意见书。 本法律意见书 ...

证券代码：001207 证券简称：联科科技 公告编号：2025-092 山东联科科技股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、特别提示 （一）本次会议上无否决或修改议案的情况。 （二）本次会议上没有新提案提交表决。 二、会议召开情况 1、股东会届次：2025 年第三次临时股东会 2、会议召集人：山东联科科技股份有限公司（以下简称"公司"）董事会 3、会议主持人：董事长吴晓林先生 4、会议召开方式：本次股东会采取现场会议与网络投票相结合的方式 5、会议召开日期、时间： （1）现场会议时间：2025 年 12 月 04 日（星期四）下午 15:00。 （2）网络投票时间：2025 年 12 月 04 日（星期四） 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 12 月 04 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 1 04 日 9:15—15:00 的任意时间。 6、股权登记日：2025 年 11 月 27 日（星期四）。 7、现场会议召开地点：山东省 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for its stock performance in the near term [6]. Core Insights - The company is set to launch a metal extraction agent project with an expected production capacity of 10,000 tons per year by the end of the year, which is anticipated to generate significant revenue [1]. - The company is the sole supplier of special carbon black for high-voltage cables in China, with a production capacity of 50,000 tons per year for its first phase project, which has entered trial production [2]. - A second phase project for high-voltage cable shielding materials is under construction, with an expected launch in mid-2026, further expanding the company's product offerings in the high-voltage cable market [3]. Financial Summary - Projected revenues for 2025, 2026, and 2027 are estimated at 30.95 billion, 37.04 billion, and 47.84 billion respectively, with net profits of 3.75 billion, 4.18 billion, and 5.69 billion [4]. - The company’s revenue growth rates are projected at 36.59% for 2025, 19.68% for 2026, and 29.15% for 2027, indicating strong growth potential [4]. - The earnings per share (EPS) is expected to increase from 1.36 in 2024 to 2.63 in 2027, reflecting a positive trend in profitability [4].

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]

证券代码：001207 证券简称：联科科技 公告编号：2025-089 山东联科科技股份有限公司 关于拟变更会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、山东联科科技股份有限公司（以下简称"公司"）此前年度 聘任的会计师事务所为永拓会计师事务所（特殊普通合伙）（以下简 称"永拓会计师事务所"），现拟聘任致同会计师事务所（特殊普通 合伙）（以下简称"致同会计师事务所"）为公司2025年度审计机构。 2、鉴于前任会计师事务所已连续多年为公司提供审计服务，为 确保公司审计工作的独立性和客观性，结合公司经营发展需要以及对 审计服务实际需求，公司拟聘请致同会计师事务所担任公司2025年度 财务决算审计和内部控制审计机构。 3、本次变更会计师事务所事项符合财政部、国务院国资委、证 监会印发的《国有企业、上市公司选聘会计师事务所管理办法》（财 会〔2023〕4号）的规定。 4、公司董事会及董事会审计委员会已审议通过拟变更会计师事 务所的议案。 公司于2025年11月17日召开第三届董事会第十二次会议、第三届 董事会审计委员会第十一次会议 ...